Xeris Biopharma Holdings, Inc.
High uncertainty:The valuation methods show significant disagreement (>100% spread). Treat the range as a rough guide rather than a precise estimate.
Bear Case (25th pct.)
-92.0% vs price
Base Case (Median)
-56.5% vs price
Bull Case (75th pct.)
80.8% vs price
◇ = Current price | |Bear |Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $43.30 | 389.3% | High (40%) |
| EV/EBITDA | $0.79 | -91.0% | Medium (20%) |
| EV/FCF | $6.90 | -22.0% | Medium (20%) |
| Earnings Power Value | $0.46 | -94.8% | Medium (50%) |
Based on 4 out of 8 methods, XERS appears fairly valued at the current price of $8.85. The base case fair value of $3.85 implies 56.5% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.